Clinical Trial: Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule.
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Observational [Patient Registry]
Official Title: A Registry Study to Surveil Early Liver Injuries Caused by Xianlin Gubao Capsule (XLGB Capsule)
Brief Summary: This is a prospective registry study to surveil early liver injuries caused by Xianlin Gubao Capsule (XLGB Capsule) through a non-intervention observational way. And attempt to establish a predictive model to screen susceptibilities to XLGB Capsule.
Detailed Summary:
The primary objectives of this study include:
(i) The detection of patients with serum liver biochemistry abnormalities within 8 weeks after intake of XLGB Capsule; (ii) The record of overall individuals with demographics, underlying diseases, physical status, medication information, clinical laboratory index, and so on; (iii) The specimen collection of surveiled individuals. (iv) The attempt to establish a predictive model to screen susceptibilities to XLGB Capsule.
Sponsor: Beijing 302 Hospital
Current Primary Outcome: The detection of patients with serum liver biochemistry abnormalities within 8 weeks after intake of XLGB Capsule. [ Time Frame: participants will be followed duration intake of XLGB Capsule, an expected average within 8 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Clinical features of early liver injuries caused by XLGB Capsule assessed by serum parameters of liver function. [ Time Frame: participants will be followed duration intake of XLGB Capsule, an expected average of 8 weeks ]
Original Secondary Outcome: Same as current
Information By: Beijing 302 Hospital
Dates:
Date Received: March 10, 2017
Date Started: March 25, 2017
Date Completion: December 31, 2017
Last Updated: March 21, 2017
Last Verified: March 2017